Ltr Pharma Fpo has released a press release.
FY25 Results Announcement
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from LTR Pharma
- Appendix 4E and Annual Report to Shareholders
- SPONTAN Case Series - Strong Post-Prostatectomy Results
- 18-Month Shelf Life Strengthens SPONTAN Commercialisation
- SPONTAN 5x Faster Onset Validated in EU Journal
- LTP Completes Extractables Study Milestone for SPONTAN
Later from LTR Pharma
- LTR Pharma secures 33% ownership in LevOmega Pty Ltd
- LTR increases LevOmega stake to 43% with $1m investment
- Ethics Approval Received for SPONTAN Phase II Clinical Study
- TGA Provides Regulatory Clearance for SPONTAN Phase II
- First Patients Dosed in SPONTAN Phase II Clinical Study
Follow LTR Pharma into a list and get an email when it puts out news.
Follow LTR Pharma